Switch to Vildagliptin, oral hypoglycemic agent therapy, from Liraglutide injection (SWITCH-2)

Switch to Vildagliptin, oral hypoglycemic agent therapy, from Liraglutide injection (SWITCH-2) - SWITCH-2

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008944

Enrollment

Registered

2012-09-19

Start date

2012-08-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 Diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)type2 diabetes treated with Liraglutide or combined therapy with Liraglutide and sulfonylurea 2)5.2%<=HbA1c(JDS)<7.0% or [FBS<110mg/dl and 2h glucose <200mg/dl] 3)over 20 years old 4)patients who agree to join the study

Exclusion criteria

Exclusion criteria: 1)severe hepatic dysfunction(ALT or AST more than 2.5times of normal value) 2)undergo dialysis 3)NYHA Classification:3or4 4)pregnancy 5)past history of the allergy to Vildagliptin 6)severe infection, before and after operation, severe trauma 7)patients who need insulin therapy 8)patients who are judged to be ineligible by the investigator for some reason

Design outcomes

Primary

Measure	Time frame
The difference in clinical features among the successful patients	—

Secondary

Measure	Time frame
1) beta-cell function determined by meal tolerance test 2) incidence of adverse event 3) change in the questionnaire about QOL 4) cost benefit 5) HbA1c and continuation of Vildagliptin at 3 and 6 month after admission	—

Countries

Japan

Contacts

Public ContactKatsutaro Morino

Shiga University of Medical Science Department of Medicine

077-548-2223

Outcome results